The Global ESG Rules and Regulations in the Pharmaceutical Industry: AstraZeneca Case Study
In the dynamic pharmaceutical sector, where innovation and regulatory compliance have long been the pillars of success, a new disruptive force is emerging: Environmental, Social, and Governance (ESG) principles
April 21, 2025
by David Orchard-Webb
What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca?
On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
October 18, 2024
by wan
AstraZeneca revenues soar with nearly $4bn in Covid-19 vaccine sales
The drugmaker, which is just beginning to profit from its Covid-19 vaccine, has recorded $37.4bn in revenue.
February 11, 2022
by Pharmaceutical-Technology
AstraZeneca reports 41% growth in FY 2021 total revenue
Total revenue for the Covid-19 sector was recorded at $4.11bn in FY 2021.
February 11, 2022
by Pharmaceutical-Technology
AstraZeneca-Daiichi Sankyo’s breast cancer therapy gets FDA priority review
The sBLA is based on results from the international, open-label Phase III DESTINY-Breast03 trial of Enhertu.
January 19, 2022
by Pharmaceutical-Technology
New AstraZeneca treatment for rare cancer reduces risk of death
Imfinzi has shown improvements in the overall survival of patients with biliary tract cancer
January 19, 2022
by pharmatimes
BenevolentAI and AstraZeneca expand drug discovery partnership
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.
January 17, 2022
by Pharmaceutical-Technology
AstraZeneca welcomes US government’s announcement to purchase additional 500,000 doses of Evusheld
Evusheld has Emergency Use Authorisation (EUA) for pre-exposure prophylaxis (prevention) of COVID-19.
January 14, 2022
by ExpressPharma
New Vaxzevria data further support its use as third dose booster
Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster...
January 14, 2022
by WorldPharmaNews
AstraZeneca, Ovid Therapeutics Partner Against Epilepsy
Transaction is the first business development activity that seeks to enhance Ovid’s pipeline of small-molecule and genetic CNS medicines.
January 3, 2022
by contractpharma
AstraZeneca, Ionis close deal on antisense therapy development
under the deal, AstraZeneca will manage the development and marketing of the antisense therapy globally.
December 30, 2021
by pharmaceutical-business-review
AstraZeneca’s Vaccine, Dumped by the West, Helps Fill Gaping Need in Rest of World
AstraZeneca's COVID-19 vaccine Vaxzevria in not authorised in the US, and other countries such as Canada, Australia and those in Western Europe have shunned it after production problems
December 27, 2021
by FirstWordPharma